Alex Philippidis

First-ever clinical demonstration in humans benefits two other public companies focused on the rapidly growing modality Credit: Christoph Burgstedt

The financing lifts the total capital raised by Seaport to $325 million since the company launched in April with an oversubscribed $100 million Series A financing

Alicia Zhou, PhD, became CRI’s president effective August 26, and succeeded Jill O’Donnell-Tormey, PhD, who had led the Institute since 1993.

Credit: Kateryna Kon / Science Photo Library / Getty Images Roche will apply Dyno Therapeutics' engineered adeno-associated virus (AAV) capsid

Shares of Sangamo Therapeutics surged 69% after the genetic medicines developer announced regulatory progress in its quest to develop its wholly owned gene therapy for Fabry disease.

MRT-6160 is now under study in a first-in-humans Phase I single ascending dose/multiple ascending dose healthy volunteer trial (NCT06597799) designed to assess the drug for immune-mediated conditions.

REC-3964 is designed to treat C. diff by selectively inhibiting the glucosyltransferase activity of toxin B produced by the bacterium in the gastrointestinal tract.

As research institutions worldwide expand their spatial efforts, providers of spatial technology consolidate, shaking up GEN’s Top 10 Spatial Biology Companies rankings.

GEM-X powers next-gen successor to Chromium Flex, new Universal Multiplex offering; new chemistry introduced for CellScape platform

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and obesity.